AI brief from 2 reports (GOV.UK news and announcements)
MHRA approves new oral treatments for plaque psoriasis and severe alopecia areata (Leqselvi)
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved two new oral treatments: one for moderate to severe plaque psoriasis and another (deuruxolitinib, brand name Leqselvi) for adults with severe alopecia areata. The MHRA notes ongoing safety and effectiveness monitoring for deuruxolitinib. 1,2
Approval of a new oral treatment for moderate to severe plaque psoriasis. 1
Approval of deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults. 2
MHRA states it will maintain close review of safety and effectiveness of deuruxolitinib after approval. 2
2026-10-23: MHRA approves new oral treatment for moderate to severe plaque psoriasis. 1
2026-10-23: MHRA approves deuruxolitinib (Leqselvi) for severe alopecia areata in adults. 2
The reports
| # | Report | Outlet | Date |
|---|---|---|---|
| 1 | MHRA approves new oral treatment for moderate to severe plaque psoriasis MHRA approves new oral treatment for moderate to severe plaque psoriasis | GOV.UK news and announcements | |
| 2 | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review. | GOV.UK news and announcements |
What the AI left out (1)
- No information on the specific names of the psoriasis treatment or detailed clinical data is provided in the sources.